Chemotherapy Remains Effective After Immunotherapy for Pleural Mesothelioma
A new real-world study from Germany brings encouraging news for pleural mesothelioma patients: the well-known chemotherapy combination of platinum and pemetrexed (Alimta) continues to work well even after immunotherapy. For patients wondering what comes next after first-line treatment, this research offers meaningful reassurance.
Pleural mesothelioma, most commonly caused by prior asbestos exposure, is one of the most challenging cancers to treat. In recent years, the immunotherapy combination of nivolumab and ipilimumab has become a standard first-line treatment for many patients. But until now, doctors have had limited evidence to guide decisions once immunotherapy stops controlling the disease.
There is currently no approved standard second-line treatment after first-line immunotherapy for mesothelioma. This study, published in Clinical Lung Cancer, helps fill that gap by examining what happens in actual clinical practice.
What Researchers Found
The study analyzed data from the German MesoNet registry, covering 135 patients treated at 12 cancer centers who received nivolumab and ipilimumab as their initial treatment. Key findings include:
- 42% of patients (57 out of 135) were healthy enough to receive a second round of treatment after their cancer progressed
- Among those patients, nearly three-quarters received platinum-based chemotherapy combined with pemetrexed
- Patients treated with this chemotherapy lived a median of 11.5 months after starting second-line treatment
- Cancer remained controlled for a median of 5.8 months before growing again
- 28% experienced partial tumor shrinkage, while 47% had stable disease
- Overall, 72% achieved disease control
These results are remarkably similar to outcomes seen when the same chemotherapy is used as a first treatment, suggesting that prior immunotherapy does not reduce the effectiveness of platinum and pemetrexed.
An Important Reality: Treatment Attrition
One of the study’s most striking findings was how quickly some patients became too ill for additional treatment. More than half of patients who started immunotherapy never received a second-line therapy. Their disease either progressed too rapidly and/or their overall health declined.
Only 16% of the original group went on to receive a third line of treatment. This highlights the aggressive nature of pleural mesothelioma and emphasizes why doctors often recommend planning future treatment options early, before a patient’s condition deteriorates.
Consistent Results Across Countries
Researchers compared their findings with similar studies from the Netherlands and Japan. All three reported very similar results, particularly for progression-free survival after chemotherapy. This consistency across different healthcare systems strengthens confidence that platinum and pemetrexed remain a reliable second-line option worldwide.
What This Means for Patients
While immunotherapy has transformed mesothelioma treatment, this study shows that chemotherapy still plays an important place in patient care. Rather than becoming ineffective after immunotherapy, platinum and pemetrexed continued to provide meaningful disease control for many patients.
The findings also reinforce an important lesson: because mesothelioma can progress rapidly, timely evaluation for additional treatment is essential. Patients who remain well enough to receive subsequent therapies have more opportunities to benefit from available treatments.
Limitations to Keep in Mind
This was a retrospective analysis (looking back at medical records), not a randomized clinical trial. Only 43 patients were treated with platinum and pemetrexed, limiting the strength of some conclusions. Future prospective studies are needed to determine the best sequence of treatments and identify which patients benefit most.
Several clinical trials are already underway evaluating new therapies for patients whose disease progresses after immune checkpoint inhibitors.
Source: German MesoNet registry study, published in Clinical Lung Cancer, 2026.
Free Mesothelioma Patient & Treatment Guide
We’d like to offer you our in-depth guide, “A Patient’s Guide to Mesothelioma,” absolutely free of charge.
It contains a wealth of information and resources to help you better understand the condition, choose (and afford) appropriate treatment, and exercise your legal right to compensation.
Download Now